AffyXell Therapeutics
Latest round
- Series A
Last raised
- Feb 2021
Total raised
- $7.3M
Investors
- 7
About AffyXell Therapeutics
AffyXell Therapeutics is a biotechnology company founded in 2020 in Gimhae, South Korea. The company focuses on developing next-generation therapies for immune regulation.AffyXell Therapeutics specializes in developing next-generation cell and gene therapies, primarily leveraging advanced technologies in mesenchymal stem cells (MSCs) and the Affimer® platform. Their core offerings focus on innovative therapeutics designed to restore immune balance and address diseases arising from immune system imbalances, such as autoimmune disorders and transplant rejection. By integrating DW-MSC platform capabilities for large-scale manufacturing with the Affimer® technology, AffyXell aims to create optimized therapies categorized under the AFX platform, specifically designed to enhance immunomodulatory functions.AffyXell Therapeutics conducts its business through strategic partnerships and collaborations within the biopharmaceutical sector, primarily targeting healthcare institutions and research organizations. The company’s revenue is generated through development agreements and potential licensing deals related to its flagship AFX platform, which includes innovative therapies for immune regulation. The transactional structure often involves milestone payments linked to developmental progress, as well as royalties based on future sales of their therapeutic products. The company aims to introduce new products focused on immune regulation and expand its reach into European and North American markets by 2023. These strategic initiatives will support their mission of delivering advanced therapies to healthcare providers and institutions, enhancing patient care in complex immune-related conditions.
Who invested in AffyXell Therapeutics
7 investors across 1 round
See all investors in AffyXell Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 1, 2021
Amount
$7.3M
Investors
Questions about AffyXell Therapeutics
Who invested in AffyXell Therapeutics?
AffyXell Therapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AffyXell Therapeutics raised?
AffyXell Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AffyXell Therapeutics last raise money?
AffyXell Therapeutics's most recent round on record is a Series A, in Feb 2021.
What does AffyXell Therapeutics do?
AffyXell Therapeutics is a biotechnology company founded in 2020 in Gimhae, South Korea.
Where is AffyXell Therapeutics headquartered?
AffyXell Therapeutics is headquartered in Gimhae, South Korea.
Which VCs invest in companies like AffyXell Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at AffyXell Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like AffyXell Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.